User profiles for Matthias Kroiss

Matthias Kroiss

University Hospital Munich
Verified email at med.lmu.de
Cited by 11317

Adrenocortical carcinoma: a clinician's update

M Fassnacht, R Libé, M Kroiss, B Allolio - Nature Reviews …, 2011 - nature.com
Adrenocortical carcinoma is a rare heterogeneous neoplasm with an incompletely understood
pathogenesis and a poor prognosis. Previous studies have identified overexpression of …

[HTML][HTML] Combination chemotherapy in advanced adrenocortical carcinoma

…, DE Schteingart, W Arlt, M Kroiss… - … England Journal of …, 2012 - Mass Medical Soc
Background Adrenocortical carcinoma is a rare cancer that has a poor response to cytotoxic
treatment. Methods We randomly assigned 304 patients with advanced adrenocortical …

Integrated genomic characterization of adrenocortical carcinoma

…, F René-Corail, N Elarouci, S Sbiera, M Kroiss… - Nature …, 2014 - nature.com
Adrenocortical carcinomas (ACCs) are aggressive cancers originating in the cortex of the
adrenal gland 1 . Despite overall poor prognosis, ACC outcome is heterogeneous 2 , 3 . We …

Targeted molecular analysis in adrenocortical carcinomas: a strategy toward improved personalized prognostication

…, A Rosenwald, CR Müller, M Kroiss… - The Journal of …, 2018 - academic.oup.com
Context Adrenocortical carcinoma (ACC) has a heterogeneous prognosis, and current medical
therapies have limited efficacy in its advanced stages. Genome-wide multiomics studies …

[HTML][HTML] Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in …

…, E Rapizzi, M Menschikowski, D Aust, M Kroiss… - Genetics in …, 2019 - Elsevier
Purpose Metabolic aberrations have been described in neoplasms with pathogenic variants
(PV) in the Krebs cycle genes encoding succinate dehydrogenase (SDH), fumarate …

[PDF][PDF] Comprehensive pan-genomic characterization of adrenocortical carcinoma

…, P Sipahimalani, A Tam, N Thiessen, PJ Park, M Kroiss… - Cancer cell, 2016 - cell.com
We describe a comprehensive genomic characterization of adrenocortical carcinoma (ACC).
Using this dataset, we expand the catalogue of known ACC driver genes to include …

[HTML][HTML] Efficacy of Selpercatinib in RET-Altered Thyroid Cancers

…, J Laskin, MH Taylor, M Kroiss… - … England Journal of …, 2020 - Mass Medical Soc
Background RET mutations occur in 70% of medullary thyroid cancers, and RET fusions
occur rarely in other thyroid cancers. In patients with RET-altered thyroid cancers, the efficacy …

Personalized management of pheochromocytoma and paraganglioma

…, F Beuschlein, M Fassnacht, M Kroiss… - Endocrine …, 2022 - academic.oup.com
Pheochromocytomas/paragangliomas are characterized by a unique molecular landscape
that allows their assignment to clusters based on underlying genetic alterations. With around …

Update in adrenocortical carcinoma

M Fassnacht, M Kroiss, B Allolio - The Journal of Clinical …, 2013 - academic.oup.com
Adrenocortical carcinoma (ACC) is an orphan malignancy that has attracted increasing
attention during the last decade. Here we provide an update on advances in the field since our …

Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study

…, MJ Demeure, J Gilbert, H Haak, M Kroiss… - The lancet …, 2015 - thelancet.com
Background Adrenocortical carcinoma is a rare, aggressive cancer for which few treatment
options are available. Linsitinib (OSI-906) is a potent, oral small molecule inhibitor of both IGF…